Data on rFVIIa use were available for analysis in six major procedures treated with rFVIIa, rFVIIa + AF, or rFVIIa + PT ± AF, with 100% of treatments rated effective for rFVIIa (1/1) and rFVIIa + AF (2/2); 0% (0/3) of treatments were rated effective for rFVIIa + PT ± AF (Table 2A). This evidence concerns the gene F2 and atrial fibrillation.